Pralsetinib vs Selpercatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: RET · full Non-Small Cell Lung Cancer pipeline
Pralsetinib
Marketed by Rigel Pharmaceuticals and partners
NCT04222972 · Phase 3 · terminated
This was a randomized, active-controlled trial in 223 patients that met its primary progression-free-survival endpoint with a clear statistical result, but it was conducted open-label (patients and investigators knew which treatment was given), which limits confidence in an investigator-assessed endpoint like progression.
Next expected readout: November 2026 · NCT04302025 (registry estimate)
Reported efficacy
Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5) (met)
Result source: NCT04222972
Selpercatinib · Retevmo
Marketed by Eli Lilly and partners
NCT04194944 · Phase 3 · active, not recruiting
LIBRETTO-431 randomised 261 patients with RET fusion-positive NSCLC to selpercatinib or platinum-pemetrexed chemotherapy with or without pembrolizumab. Treatment was open-label, but progression was assessed by blinded independent central review. The primary endpoint, progression-free survival, was met (HR 0.465, 95% CI 0.309 to 0.699, p=0.0002 against chemotherapy plus pembrolizumab); the open-label design keeps the grade at moderate.
Next expected readout: December 2026 · NCT04268550 (registry estimate)
Reported efficacy
Event-Free Survival (EFS) (Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)): Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026) (met)
Result source: NCT04819100
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pralsetinib | Selpercatinib |
|---|---|---|
| PFS, median | 18.7 vs 9vs SOCNCT042229726 other results
| 24.8 vs 11.2vs Pemetrexed and Platinum With PembrolizumabNCT041949441 other result
|
| OS, median | 39.7bNCT030373854 other results
| 33.0NCT04194944 |
| ORR | 65.5% vs 41.6%vs SOCNCT0422297218 other results
| 83.7% vs 65.1%vs Pemetrexed and Platinum With PembrolizumabNCT041949441 other result
|
| Duration of response, median | 20.6 vs 9.7vs SOCNCT042229727 other results
| 24.2 vs 11.5vs Pemetrexed and Platinum With PembrolizumabNCT041949441 other result
|
PFS, median
- Pralsetinib
- 18.7 vs 9vs SOCNCT04222972
6 other results
- 16.4 NCT03037385
- 12.1 NCT03037385
- 13 NCT03037385
- 24.9 NCT03037385
- 55.3 NCT03037385
- 7 NCT03037385
- Selpercatinib
- 24.8 vs 11.2vs Pemetrexed and Platinum With PembrolizumabNCT04194944
1 other result
- 24.8 vs 11.2 NCT04194944
OS, median
- Pralsetinib
- 39.7bNCT03037385
4 other results
- 50.1 NCT03037385
- 46 NCT03037385
- 42.2 NCT03037385
- 10.3 NCT03037385
- Selpercatinib
- 33.0NCT04194944
ORR
- Pralsetinib
- 65.5% vs 41.6%vs SOCNCT04222972
18 other results
- 63.1% NCT03037385
- 78.3% NCT03037385
- 73.9% NCT03037385
- 56.7% NCT03037385
- 77.8% NCT03037385
- 85.2% NCT03037385
- 46.4% NCT03037385
- 19% NCT03037385
- 7.7% NCT03037385
- 41.7% NCT03037385
- 45.5% NCT03037385
- 38.5% NCT03037385
- 25% NCT03037385
- 75% NCT03037385
- 40% NCT03037385
- 80% NCT03037385
- 50% NCT03037385
- 0% NCT03037385
- Selpercatinib
- 83.7% vs 65.1%vs Pemetrexed and Platinum With PembrolizumabNCT04194944
1 other result
- 83.6% vs 62.7% NCT04194944
Duration of response, median
- Pralsetinib
- 20.6 vs 9.7vs SOCNCT04222972
7 other results
- 31.8 NCT03037385
- 13.4 NCT03037385
- 22.6 NCT03037385
- 21.7 NCT03037385
- 51.8 NCT03037385
- 11.1 NCT03037385
- 5.5 NCT03037385
- Selpercatinib
- 24.2 vs 11.5vs Pemetrexed and Platinum With PembrolizumabNCT04194944
1 other result
- 24.2 vs 12.0 NCT04194944
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Pralsetinib: 4 of 5 rows · Selpercatinib: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pralsetinib | Selpercatinib |
|---|---|---|
| Disease Control responder rate · % of participants | 88.2% (n=110) vs 79.6% (n=113) SOCa,b NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 | 89.1% (n=129) vs 84.3% (n=83) Pemetrexed and Platinum With Pembrolizumabc,a,b NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 1 more dose89.3% (n=159) vs 82.4% (n=102) Pemetrexed and Platinum With or Without Pembrolizumab NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Dropout rate | n/a: no completion milestoned NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 10 more resultsn/a: no completion milestone400 mg NCT03037385 · Phase 1/2 —400 mg QD NCT03037385 · Phase 1/2 n/a: no completion milestone600 mg NCT03037385 · Phase 1/2 n/a: no completion milestone300 mg NCT03037385 · Phase 1/2 n/a: no completion milestone200 mg NCT03037385 · Phase 1/2 n/a: no completion milestone200/100 mg NCT03037385 · Phase 1/2 n/a: no completion milestone100 mg NCT03037385 · Phase 1/2 n/a: no completion milestone100/100 mg NCT03037385 · Phase 1/2 n/a: no completion milestone60 mg NCT03037385 · Phase 1/2 n/a: no completion milestone30 mg NCT03037385 · Phase 1/2 | 61.6% NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | 0.9%d NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 10 more results0%400 mg NCT03037385 · Phase 1/2 —400 mg QD NCT03037385 · Phase 1/2 0%600 mg NCT03037385 · Phase 1/2 0%300 mg NCT03037385 · Phase 1/2 0%200 mg NCT03037385 · Phase 1/2 0%200/100 mg NCT03037385 · Phase 1/2 20%100 mg NCT03037385 · Phase 1/2 0%100/100 mg NCT03037385 · Phase 1/2 0%60 mg NCT03037385 · Phase 1/2 0%30 mg NCT03037385 · Phase 1/2 | — NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 62%d NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 10 more results—400 mg NCT03037385 · Phase 1/2 70.6%400 mg QD NCT03037385 · Phase 1/2 —600 mg NCT03037385 · Phase 1/2 —300 mg NCT03037385 · Phase 1/2 —200 mg NCT03037385 · Phase 1/2 —200/100 mg NCT03037385 · Phase 1/2 —100 mg NCT03037385 · Phase 1/2 —100/100 mg NCT03037385 · Phase 1/2 —60 mg NCT03037385 · Phase 1/2 —30 mg NCT03037385 · Phase 1/2 | 34.8% NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | d anaemia 48.1% constipation 43.5% aspartate aminotransferase increased 41.7% NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 1 more result400 mg QD anaemia 52.8% aspartate aminotransferase increased 50.6% constipation 44.1% NCT03037385 · Phase 1/2 | aspartate aminotransferase increased 61.4% alanine aminotransferase increased 60.1% hypertension 48.1% NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 |
Notes
- aTreatment context has not been resolved for both arms.
- bThe assessment timepoint is not available for both results.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation comparability has not been reviewed for 10 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pralsetinib
show 17 more results
show 8 more results
show 8 more results
show 8 more results
show 6 more results
show 6 more results
show 1 more result
Selpercatinib
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pralsetinib's landscape · Selpercatinib's landscape